基于心血管疾病与死亡风险定义的最佳健康甲状腺功能范围:系统综述与个体参与者数据荟萃分析
该系统综述与个体参与者数据荟萃分析纳入26个前瞻性队列的134346名成人,分析TSH与FT4和心血管疾病及死亡风险的关联。FT4与复合结局呈J型关联,20-40百分位风险最低;TSH呈非线性关联,60-80百分位风险最低。FT4 20-40百分位和TSH 60-80百分位可能代表最佳健康范围。
要点
- FT4与心血管疾病及死亡风险呈J型关联,20-40百分位风险最低。
- TSH与风险呈非线性关联,60-80百分位心血管疾病及死亡风险最低。
- 70岁及以上女性FT4>85百分位、男性>75百分位时10年复合风险增加超过5%。
核心结论
- FT4与心血管疾病及死亡呈J型关联,低TSH与全因死亡和心血管死亡风险升高相关。
- FT4 20-40百分位和TSH 60-80百分位可能代表基于心血管疾病与死亡风险的最佳健康甲状腺功能范围。
- 70岁以上女性FT4>85百分位、男性>75百分位时10年复合风险增加超过5%。
研究设计与样本
- 通过Thyroid Studies Collaboration识别前瞻性队列,并系统检索Embase、MEDLINE(Ovid)、Web of Science、Cochrane Central Register of Controlled Trials和Google Scholar(2011年1月1日至2017年2月12日,更新检索至2022年10月13日,第二次检索发现的队列未纳入IPD)。
- 纳入收集TSH或FT4及心血管结局或死亡数据的成人(年龄≥18岁)队列,排除仅含孕妇、明显甲状腺疾病患者和心血管疾病患者的队列。
- 共识别3935项研究,53个队列符合纳入标准,26个队列同意参与,纳入134346名参与者的个体参与者数据,基线中位年龄59岁(范围18-106)。
- 采用一步法(队列分层Cox模型)和两步法(随机效应模型)荟萃分析,调整年龄、性别、吸烟、收缩压、糖尿病和总胆固醇。
- 研究注册于PROSPERO,CRD42017057576。
主要发现
- FT4与复合结局及次要结局呈J型关联,20百分位(中位数13.5 pmol/L,IQR 11.2-13.9)至40百分位(中位数14.8 pmol/L,IQR 12.3-15.0)风险最低。
- 与20-40百分位相比,FT4 80-100百分位的年龄和性别调整HR:复合结局1.20(95% CI 1.11-1.31),全因死亡1.34(95% CI 1.20-1.49),心血管死亡1.57(95% CI 1.31-1.89),心血管疾病事件1.22(95% CI 1.11-1.33)。
- 70岁及以上人群中,女性FT4>85百分位(中位数17.6 pmol/L,IQR 15.0-18.3)和男性FT4>75百分位(16.7 pmol/L,IQR 14.0-17.4)时,10年复合结局绝对风险增加超过5%。
- TSH呈非线性关联,60百分位(中位数1.90 mIU/L,IQR 1.68-2.25)至80百分位(2.90 mIU/L,IQR 2.41-3.32)心血管疾病和死亡风险最低。
- 与60-80百分位相比,TSH 0-20百分位的年龄和性别调整HR:复合结局1.07(95% CI 1.02-1.12),全因死亡1.09(95% CI 1.05-1.14),心血管死亡1.07(95% CI 0.99-1.16)。
关键数值与推荐
- FT4与复合结局及次要结局呈J型关联,20-40百分位风险最低。
- TSH与心血管疾病和死亡风险呈非线性关联,60-80百分位风险最低。
- FT4 80-100百分位相比20-40百分位,复合结局HR 1.20(95% CI 1.11-1.31),全因死亡HR 1.34(95% CI 1.20-1.49),心血管死亡HR 1.57(95% CI 1.31-1.89),心血管疾病事件HR 1.22(95% CI 1.11-1.33)。
- TSH 0-20百分位相比60-80百分位,复合结局HR 1.07(95% CI 1.02-1.12),全因死亡HR 1.09(95% CI 1.05-1.14),心血管死亡HR 1.07(95% CI 0.99-1.16)。
临床怎么用
- 作者提出一种可行方法以建立最佳健康甲状腺功能范围,有助于更好识别甲状腺相关结局风险较高的个体。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Reference intervals of thyroid-stimulating hormone (TSH) and free thyroxine (FT4) are statistically defined by the 2·5-97·5th percentiles, without accounting for potential risk of clinical outcomes. We aimed to define the optimal healthy ranges of TSH and FT4 based on the risk of cardiovascular disease and mortality. METHODS: This systematic review and individual participant data (IPD) meta-analysis identified eligible prospective cohorts through the Thyroid Studies Collaboration, supplemented with a systematic search via Embase, MEDLINE (Ovid), Web of science, the Cochrane Central Register of Controlled Trials, and Google Scholar from Jan 1, 2011, to Feb 12, 2017 with an updated search to Oct 13, 2022 (cohorts found in the second search were not included in the IPD). We included cohorts that collected TSH or FT4, and cardiovascular outcomes or mortality for adults (aged ≥18 years). We excluded cohorts that included solely pregnant women, individuals with overt thyroid diseases, and individuals with cardiovascular disease. We contacted the study investigators of eligible cohorts to provide IPD on demographics, TSH, FT4, thyroid peroxidase antibodies, history of cardiovascular disease and risk factors, medication use, cardiovascular disease events, cardiovascular disease mortality, and all-cause mortality. The primary outcome was a composite outcome including cardiovascular disease events (coronary heart disease, stroke, and heart failure) and all-cause mortality. Secondary outcomes were the separate assessment of cardiovascular disease events, all-cause mortality, and cardiovascular disease mortality. We performed one-step (cohort-stratified Cox models) and two-step (random-effects models) meta-analyses adjusting for age, sex, smoking, systolic blood pressure, diabetes, and total cholesterol. The study was registered with PROSPERO, CRD42017057576. FINDINGS: We identified 3935 studies, of which 53 cohorts fulfilled the inclusion criteria and 26 cohorts agreed to participate. We included IPD on 134 346 participants with a median age of 59 years (range 18-106) at baseline. There was a J-shaped association of FT4 with the composite outcome and secondary outcomes, with the 20th (median 13·5 pmol/L [IQR 11·2-13·9]) to 40th percentiles (median 14·8 pmol/L [12·3-15·0]) conveying the lowest risk. Compared with the 20-40th percentiles, the age-adjusted and sex-adjusted hazard ratio (HR) for FT4 in the 80-100th percentiles was 1·20 (95% CI 1·11-1·31) for the composite outcome, 1·34 (1·20-1·49) for all-cause mortality, 1·57 (1·31-1·89) for cardiovascular disease mortality, and 1·22 (1·11-1·33) for cardiovascular disease events. In individuals aged 70 years and older, the 10-year absolute risk of composite outcome increased over 5% for women with FT4 greater than the 85th percentile (median 17·6 pmol/L [IQR 15·0-18·3]), and men with FT4 greater than the 75th percentile (16·7 pmol/L [14·0-17·4]). Non-linear associations were identified for TSH, with the 60th (median 1·90 mIU/L [IQR 1·68-2·25]) to 80th percentiles (2·90 mIU/L [2·41-3·32]) associated with the lowest risk of cardiovascular disease and mortality. Compared with the 60-80th percentiles, the age-adjusted and sex-adjusted HR of TSH in the 0-20th percentiles was 1·07 (95% CI 1·02-1·12) for the composite outcome, 1·09 (1·05-1·14) for all-cause mortality, and 1·07 (0·99-1·16) for cardiovascular disease mortality. INTERPRETATION: There was a J-shaped association of FT4 with cardiovascular disease and mortality. Low concentrations of TSH were associated with a higher risk of all-cause mortality and cardiovascular disease mortality. The 20-40th percentiles of FT4 and the 60-80th percentiles of TSH could represent the optimal healthy ranges of thyroid function based on the risk of cardiovascular disease and mortality, with more than 5% increase of 10-year composite risk identified for FT4 greater than the 85th percentile in women and men older than 70 years. We propose a feasible approach to establish the optimal healthy ranges of thyroid function, allowing for better identification of individuals with a higher risk of thyroid-related outcomes. FUNDING: None.
引用
- Xu Y, Derakhshan A, Hysaj O, et al. The optimal healthy ranges of thyroid function defined by the risk of cardiovascular disease and mortality: systematic review and individual participant data meta-analysis. Lancet Diabetes Endocrinol. 2023. PMID: 37696273. doi:10.1016/S2213-8587(23)00227-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。